Bexarotene: a promising anticancer agent

被引：60

作者：

Qu, Liyan ^{[1
]}

Tang, Xiuwen ^{[1
]}

机构：

[1] Zhejiang Univ, Sch Med, Dept Biochem & Genet, Hangzhou 310058, Zhejiang, Peoples R China

来源：

CANCER CHEMOTHERAPY AND PHARMACOLOGY | 2010年 / 65卷 / 02期

关键词：

Bexarotene; Cell cycle; Apoptosis; Differentiation; Multidrug resistance; X-RECEPTOR AGONIST; CELL LUNG-CANCER; OVERCOMES MULTIDRUG-RESISTANCE; CHEMOTHERAPY-NAIVE PATIENTS; NF-KAPPA-B; ORAL BEXAROTENE; PHASE-II; TARGRETIN PREVENTS; MYCOSIS-FUNGOIDES; MYELOID-LEUKEMIA;

D O I：

10.1007/s00280-009-1140-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Retinoids are biologically active derivatives of vitamin A, which play essential roles in embryonic or adult cell behavior modulating cell proliferation, differentiation and apoptosis. The biologic effects of retinoids are mediated by two distinct families of intracellular receptors: retinoid acid receptors (RARs)-alpha, -beta and -gamma and retinoid X receptors (RXR)-alpha, -beta and -gamma. Bexarotene is a selective RXR agonist, which exerts its effects in blocking cell cycle progression, inducing apoptosis and differentiation, preventing multidrug resistance, and inhibiting angiogenesis and metastasis, making it a promising chemopreventive agent against cancer.

引用

页码：201 / 205

页数：5

共 65 条

[1] Bexarotene therapy for mycosis fungoides and Sezary syndrome [J].

Abbott, R. A. ;

Whittaker, S. J. ;

Morris, S. L. ;

Russell-Jones, R. ;

Hung, T. ;

Bashir, S. J. ;

Scarisbrick, J. J. .

BRITISH JOURNAL OF DERMATOLOGY, 2009, 160 (06) :1299-1307

[2] Rexinoid-triggered differentiation and tumor-selective apoptosis of acute myeloid leukemia by protein kinase A-mediated desubordination of retinoid X receptor [J].

Altucci, L ;

Rossin, A ;

Hirsch, O ;

Nebbioso, A ;

Vitoux, D ;

Wilhelm, E ;

Guidez, F ;

De Simone, M ;

Schiavone, EM ;

Grimwade, D ;

Zelent, A ;

de Thé, H ;

Gronemeyer, H .

CANCER RESEARCH, 2005, 65 (19) :8754-8765

[3] Modulation by bexarotene of mRNA expression of genes in mouse lung tumors [J].

Alyacloub, Fadel S. ;

Liu, Yue ;

Tao, Lianhui ;

Steele, Vernon E. ;

Lubet, Ronald A. ;

Pereira, Michael A. .

MOLECULAR CARCINOGENESIS, 2008, 47 (03) :165-171

[4]

Bedikian AY, 2000, ONCOL REP, V7, P883

[5] NF-κB transcription factor induces drug resistance through MDR1 expression in cancer cells [J].

Bentires-Alj, M ;

Barbu, V ;

Fillet, M ;

Chariot, A ;

Relic, B ;

Jacobs, N ;

Gielen, J ;

Merville, MP ;

Bours, V .

ONCOGENE, 2003, 22 (01) :90-97

[6] Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II [J].

Blumenschein, George R., Jr. ;

Khuri, Fadlo R. ;

von Pawel, Joachim ;

Gatzemeier, Ulrich ;

Miller, Wilson H., Jr. ;

Jotte, Robert M. ;

Le Treut, Jacques ;

Sun, Show-Li ;

Zhang, Jinkun K. ;

Dziewanowska, Zofia E. ;

Negro-Vilar, Andres .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (11) :1879-1885

[7] SYNTHESIS AND STRUCTURE-ACTIVITY-RELATIONSHIPS OF NOVEL RETINOID-X RECEPTOR-SELECTIVE RETINOIDS [J].

BOEHM, MF ;

ZHANG, L ;

BADEA, BA ;

WHITE, SK ;

MAIS, DE ;

BERGER, E ;

SUTO, CM ;

GOLDMAN, ME ;

HEYMAN, RA .

JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (18) :2930-2941

[8]

Breneman Debra, 2007, J Drugs Dermatol, V6, P501

[9] Combination Chemoprevention of HER2/neu-Induced Breast Cancer Using a Cyclooxygenase-2 Inhibitor and a Retinoid X Receptor-Selective Retinoid [J].

Brown, Powel H. ;

Subbaramaiah, Kotha ;

Salmon, Amoi P. ;

Baker, Rebecca ;

Newman, Robert A. ;

Yang, Peiying ;

Zhou, Xi Kathy ;

Bissonnette, Reid P. ;

Dannenberg, Andrew J. ;

Howe, Louise R. .

CANCER PREVENTION RESEARCH, 2008, 1 (03) :208-214

[10] Differentiation and growth inhibition mediated via the RXR:PPARγ heterodimer in colon cancer [J].

Cesario, Rosemary M. ;

Stone, Jessica ;

Yen, Wan-Ching ;

Bissonnette, Reid P. ;

Lamph, William W. .

CANCER LETTERS, 2006, 240 (02) :225-233

← 1 2 3 4 5 6 7 →